元力股份(300174) - 2024 Q1 - 季度财报

Financial Position - The company reported a cash balance of CNY 1,523,523,300.66 as of March 31, 2024, compared to CNY 1,527,303,389.15 at the beginning of the period[21]. - Short-term borrowings increased by CNY 95,037,000, reaching a total of CNY 300,201,700 as of the end of the reporting period, primarily due to increased bank short-term loans[12]. - The company’s inventory stood at CNY 270,917,679.05, down from CNY 281,019,253.20 at the beginning of the period[21]. - The total assets amount to ¥3,870,957,324.30, showing a decrease of 2.04% from ¥3,951,679,262.57 at the end of the previous year[28]. - The total liabilities amount to ¥651,733,224.61, down from ¥719,405,233.92[23]. - The balance of trading financial assets at the end of the reporting period was 5 million, a decrease of 400 million from the beginning of the year, due to the redemption of wealth management products by the subsidiary Yihai Kerry[29]. - Other receivables at the end of the reporting period amounted to 1.5744 million, a decrease of 9.3857 million from the beginning of the year, primarily due to the transfer of 51% equity in the controlling subsidiary Yuanhe Chemical, which will no longer be included in the consolidated financial statements[29]. - The balance of long-term equity investments at the end of the reporting period was zero, down from 100.3748 million at the beginning of the year, also due to the transfer of 51% equity in Yuanhe Chemical[29]. - The balance of employee compensation payable at the end of the reporting period was 25.3009 million, a decrease of 37.62% from the beginning of the year, mainly due to year-end salary payments[31]. - Other payables at the end of the reporting period were 3.9255 million, a decrease of 114.5298 million from the beginning of the year, primarily due to the transfer of 51% equity in Yuanhe Chemical[31]. - The balance of minority shareholders' equity at the end of the reporting period was 32.7929 million, a decrease of 88.5724 million from the beginning of the year, due to the transfer of 51% equity in Yuanhe Chemical[31]. Revenue and Profitability - The total operating revenue for the current period is ¥467,219,632.07, representing a 2.15% increase compared to ¥457,401,405.40 in the same period last year[28]. - The net profit attributable to shareholders of the listed company is ¥77,630,815.17, a significant increase of 71.25% from ¥45,330,906.83 in the previous year[28]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is ¥46,977,715.37, up 4.75% from ¥44,845,657.44[28]. - The basic earnings per share is ¥0.2122, reflecting a 70.17% increase from ¥0.1247[28]. - The operating profit for the current period is 83,379,490.74, up 47.5% from 56,564,161.24 in the previous period[54]. - The total profit for the current period is 83,654,035.08, an increase of 46.6% compared to 57,070,988.14 in the previous period[54]. - The company recorded investment income of 28,234,755.33, significantly up from 8,341,552.93 in the previous period[54]. Cash Flow - The net cash flow from operating activities is -¥90,397,311.92, a decline of 82.30% compared to -¥49,586,075.07 in the previous year[28]. - The cash flow from operating activities showed a net outflow of -90,397,311.92, worsening from -49,586,075.07 in the previous period[56]. - The net increase in cash and cash equivalents at the end of the reporting period was 327.4033 million, down from 913.0431 million at the beginning of the year[46]. - Cash outflow related to investment activities was 653 million, an increase of 368 million year-on-year, primarily due to increased periodic payments[32]. Expenses and Taxation - The income tax expense for the reporting period was CNY 5,570,300, an increase of CNY 1,507,400 year-on-year due to an increase in taxable income[13]. - The company reported a decrease in tax expenses to 5,570,287.04 from 4,062,865.61, a reduction of 37.1%[54]. - Research and development expenses increased to 19,973,714.06 from 16,296,268.94, reflecting a growth of 22.0%[54]. - The sales expenses for the current period were 10,377,913.69, slightly higher than 10,022,116.01 in the previous period, reflecting an increase of 3.6%[54]. - Other income for the reporting period was 11.3646 million, an increase of 3.9871 million year-on-year, mainly due to an increase in VAT refunds and government subsidies[31]. - Investment income for the reporting period was 28.2348 million, an increase of 19.8932 million year-on-year, resulting from the transfer of 51% equity in Yuanhe Chemical[31]. Shareholder Information - The top shareholder, Wang Yan'an, holds 16.59% of the shares, totaling 60,685,476 shares[17]. - The equity attributable to shareholders of the listed company is ¥3,186,431,241.09, which is a 2.43% increase from ¥3,110,908,734.36[28]. - The weighted average return on net assets is 2.38%, an increase of 0.83% from 1.55%[28].